Bioavailability Assessment of Stiripentol Following Single Oral Administration of Two Formulations in Healthy Subjects: A Study in Dravet Syndrome Context

The primary objective of this study is to evaluate the **bioavailability** of stiripentol following a single oral administration of two different formulations: capsule and oral suspension. This assessment is conducted in 24 healthy subjects. Understanding the bioavailability of stiripentol is clinically relevant as it provides insights into the drug's absorption and systemic availability, which are critical for optimizing therapeutic efficacy and safety in treating conditions such as **Dravet syndrome**. No secondary objectives are specified for this study.

The clinical trial involves participants diagnosed with **Dravet syndrome**, a severe form of epilepsy. The study population includes both male and female subjects, with an age range starting from 3 years old. The trial specifically includes a vulnerable population, although the total number of participants has not been disclosed by the sponsor. Participants were selected based on criteria not provided in the available data. No specific lifestyle considerations such as diet, physical activity, or habits have been mentioned. The sponsor has not provided detailed information regarding the key inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the **bioavailability** of stiripentol following a single oral administration of two different formulations, namely a capsule and an oral suspension, in a cohort of 24 healthy subjects. This study is structured as a Phase 3 trial, which is a critical stage in the clinical research process, focusing on the efficacy and safety of the drug formulations. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results, minimizing bias and allowing for a robust comparison between the two formulations.

The trial is scheduled to commence recruitment on April 1, 2025, with an estimated completion date of July 31, 2025. Participants will be involved in the study for a duration that encompasses several key visits. Initially, an inclusion visit, also known as the screening visit, will be conducted to assess eligibility based on predefined criteria. This visit is crucial for ensuring that only suitable candidates are enrolled in the trial. Following the initial administration of the formulations, participants will attend follow-up visits, which are designed to monitor their health status, collect pharmacokinetic data, and assess any adverse events. These visits are integral to evaluating the primary and secondary endpoints of the study.

The end-of-study visit marks the conclusion of the participant's involvement, where final assessments are conducted to gather comprehensive data on the drug's bioavailability and safety profile. The expected length of participant involvement is determined by the trial's schedule and the number of required visits. However, certain conditions, such as adverse reactions or non-compliance with study protocols, may necessitate early termination from the study. The trial's design and procedures are meticulously planned to ensure the collection of high-quality data, contributing to the understanding of stiripentol's pharmacokinetic properties in healthy individuals.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available in the provided data.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on April 1, 2025, with an estimated completion date of July 31, 2025. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters, adhering to the standards expected in a Phase 3 clinical trial. The trial's design and execution will ensure that the efficacy assessments are conducted with scientific rigor and precision, although specific tools or instruments for these assessments are not mentioned in the available information.